These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34202178)

  • 1. Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies.
    Sei CJ; Rao M; Schuman RF; Daum LT; Matyas GR; Rikhi N; Muema K; Anderson A; Jobe O; Kroscher KA; Alving CR; Fischer GW
    Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34202178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unconjugated Multi-Epitope Peptides Adjuvanted with ALFQ Induce Durable and Broadly Reactive Antibodies to Human and Avian Influenza Viruses.
    Rikhi N; Sei CJ; Rao M; Schuman RF; Kroscher KA; Matyas GR; Muema K; Lange C; Assiaw-Dufu A; Hussin E; Jobe O; Alving CR; Fischer GW
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.
    Beck Z; Matyas GR; Jalah R; Rao M; Polonis VR; Alving CR
    Vaccine; 2015 Oct; 33(42):5578-5587. PubMed ID: 26372857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
    Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.
    Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioinformatics design and experimental validation of influenza A virus multi-epitopes that induce neutralizing antibodies.
    Ramírez-Salinas GL; García-Machorro J; Rojas-Hernández S; Campos-Rodríguez R; de Oca AC; Gomez MM; Luciano R; Zimic M; Correa-Basurto J
    Arch Virol; 2020 Apr; 165(4):891-911. PubMed ID: 32060794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.
    Prachanronarong KL; Canale AS; Liu P; Somasundaran M; Hou S; Poh YP; Han T; Zhu Q; Renzette N; Zeldovich KB; Kowalik TF; Kurt-Yilmaz N; Jensen JD; Bolon DNA; Marasco WA; Finberg RW; Schiffer CA; Wang JP
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30381484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
    Klausberger M; Tscheliessnig R; Neff S; Nachbagauer R; Wohlbold TJ; Wilde M; Palmberger D; Krammer F; Jungbauer A; Grabherr R
    PLoS One; 2016; 11(4):e0153579. PubMed ID: 27088239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges.
    Reneer ZB; Jamieson PJ; Skarlupka AL; Huang Y; Ross TM
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.
    Zost SJ; Wu NC; Hensley SE; Wilson IA
    J Infect Dis; 2019 Apr; 219(Suppl_1):S38-S45. PubMed ID: 30535315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
    He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
    J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress on adenovirus-vectored universal influenza vaccines.
    Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S
    Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
    Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
    Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice.
    Babai I; Samira S; Barenholz Y; Zakay-Rones Z; Kedar E
    Vaccine; 1999 Mar; 17(9-10):1239-50. PubMed ID: 10195637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.